Peptide & Compound Guide
At a glance
| Compound | Tirzepatide |
|---|---|
| Type | GIP/GLP-1 receptor agonist peptide medicine |
| U.S. regulatory context | FDA-approved active ingredient in prescription products for specific indications |
| Evidence level | Established clinical evidence for approved uses |
| Research area | Type 2 diabetes, obesity and related metabolic outcomes |
What is Tirzepatide?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It is the active ingredient in FDA-approved prescription products with indication-specific labeling.
What does the research examine?
Large randomized clinical trials have examined glycemic control and chronic weight management. Ongoing research continues to evaluate cardiometabolic and other outcomes.
What has not been established?
Mechanism, biomarker changes, animal findings and early clinical signals are not the same as proof that a compound safely improves meaningful health outcomes. Claims should be matched to the type, size and quality of evidence available.
Safety and regulatory context
Approved use depends on the specific product and patient. Safety, contraindications and interactions should be reviewed with a licensed clinician.
Related: Semaglutide vs. Tirzepatide · Retatrutide vs. Tirzepatide
Research sources
Use primary and authoritative sources when evaluating claims about this compound. Search results can change as new research is published.